Henry Schein Inc

Henry Schein amended and restated its revolving credit facility, increasing total commitments to $1.25 billion and extending the termination date to September 19, 2031. The medical products distributor's shares traded at $86.37, up 0.98% over one day and 1.80% over seven days, though the 30-day return slipped 3.52% while the year-to-date return stands at 12.43%. The 1-year total shareholder return of 30.74% suggests investors have read the upgraded facility and a recent guidance raise as supportive of both growth plans and perceived risk. The most followed valuation narrative pegs fair value at $98.19, above the latest close, with the company expecting more than 50% of non-GAAP operating income to come from high-margin businesses such as Specialty Products, Technology, and private-label offerings. Risks to that case include scanner pricing pressure eroding equipment margins faster than expected or multi-year analyst forecasts proving too optimistic.

Henry Schein raised its 2026 total sales growth guidance following second-quarter results that showed revenue of $3,458 million and net income of $94 million, with higher earnings per share from continuing operations compared to a year earlier. The upgraded outlook signals management’s increased confidence in operating initiatives and demand trends, reinforcing the investment narrative around margin expansion and digital growth. The company also formed a new Henry Schein Leadership Team and is integrating its global supply chain with distribution, moves that sit alongside the raised guidance as key factors for cost efficiency and value creation. However, risks remain if leadership transitions or supply chain integration face delays, potentially affecting the pace at which higher-margin segments and cost savings materialize. Henry Schein’s long-term projections target $14.9 billion in revenue and $653.3 million in earnings by 2029, implying 3.8% annual revenue growth and a $258 million increase from current earnings of $395 million.

Henry Schein Inc. reported a second-quarter profit of $94 million, or $0.82 per share, up from $86 million, or $0.70 per share, a year earlier. Excluding items, adjusted earnings were $145 million, or $1.27 per share. Revenue rose 6.7% to $3.458 billion from $3.240 billion. The company issued full-year earnings per share guidance of $5.29 to $5.39 and expects full-year revenue growth of 4.5% to 5.5%.

GoTu Technology and Henry Schein have announced a strategic partnership to help dental practices address staffing shortages. Through the collaboration, dental practices will gain expanded access to GoTu's platform, which connects offices with qualified dental hygienists, dental assistants, and associate dentists for temporary and permanent roles. GoTu will become part of Henry Schein Dental Recruitment Services, a division of Henry Schein Financial Enterprises, a wholly-owned subsidiary of Henry Schein. The partnership combines GoTu's workforce technology with Henry Schein's extensive customer network to deliver flexible staffing solutions. GoTu has filled more than 500,000 shifts nationwide, and Henry Schein serves more than 1 million customers globally.

The four dental equipment and technology stocks tracked by StockStory reported strong first-quarter results, with aggregate revenues beating analysts' consensus estimates by 3% while next-quarter revenue guidance was in line. Dentsply Sirona posted flat revenue of $880 million, exceeding expectations by 4.8%, but its stock fell 10% since reporting. Envista delivered the fastest revenue growth among its peers at 14.4% to $705.5 million, yet shares declined 6.7%. Henry Schein, the weakest performer against estimates, saw revenue rise 6.3% to $3.37 billion and its stock gained 11.2%. Align Technology reported a 6.2% revenue increase to $1.04 billion, beating estimates, but its stock dropped 6.3%. On average, share prices across the group are down 2.9% since the latest earnings results.